Abstract
The activation of vitamin D receptors (VDR) - (including activation by 25-hydroxyvitamin D) - seems to have not only mineral-metabolism beneficial effects but also important extra-skeletal actions. Paricalcitol is a synthetic vitamin D2 agonist of the VDR approved for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD). As a result of its selectivity, paricalcitol provides a wider therapeutic window for PTH suppression, minimizing deleterious effects of high serum calcium and/or phosphate concentrations. Paricalcitol also shares, and sometimes improves pleiotropic vitamin-D related systemic effects. For instance, paricalcitol has been repeatedly shown to decrease calcium and phosphate deposition in vessels and to decrease the expression of osteogenic factors preventing the active transformation of smooth muscle vascular cells into osteoblast-like cells in experimental models. In patients, paricalcitol has been associated with improved survival of dialysis patients and it may improve residual albuminuria in diabetic patients. Consequently, paricalcitol may enhance the standard of care in these high-risk patients. Although it seems reasonable to use these potential advantages to guide the individual and integral management of the complex CKD-mineral and bone disorder, it is necessary to recognize that many of these observations have not been proven nor confirmed in prospective clinical trials.
Keywords: Chronic kidney disease, CKD-MBD, paricalcitol, PTH, vascular calcification, vitamin D.
Current Vascular Pharmacology
Title:Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D2 (Paricalcitol)
Volume: 12 Issue: 2
Author(s): J. Bover, I. DaSilva, M. Furlano, M.J. Lloret, M.M. Diaz-Encarnacion, J. Ballarin and M. Cozzolino
Affiliation:
Keywords: Chronic kidney disease, CKD-MBD, paricalcitol, PTH, vascular calcification, vitamin D.
Abstract: The activation of vitamin D receptors (VDR) - (including activation by 25-hydroxyvitamin D) - seems to have not only mineral-metabolism beneficial effects but also important extra-skeletal actions. Paricalcitol is a synthetic vitamin D2 agonist of the VDR approved for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD). As a result of its selectivity, paricalcitol provides a wider therapeutic window for PTH suppression, minimizing deleterious effects of high serum calcium and/or phosphate concentrations. Paricalcitol also shares, and sometimes improves pleiotropic vitamin-D related systemic effects. For instance, paricalcitol has been repeatedly shown to decrease calcium and phosphate deposition in vessels and to decrease the expression of osteogenic factors preventing the active transformation of smooth muscle vascular cells into osteoblast-like cells in experimental models. In patients, paricalcitol has been associated with improved survival of dialysis patients and it may improve residual albuminuria in diabetic patients. Consequently, paricalcitol may enhance the standard of care in these high-risk patients. Although it seems reasonable to use these potential advantages to guide the individual and integral management of the complex CKD-mineral and bone disorder, it is necessary to recognize that many of these observations have not been proven nor confirmed in prospective clinical trials.
Export Options
About this article
Cite this article as:
Bover J., DaSilva I., Furlano M., Lloret M.J., Diaz-Encarnacion M.M., Ballarin J. and Cozzolino M., Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D2 (Paricalcitol), Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/15701611113119990028
DOI https://dx.doi.org/10.2174/15701611113119990028 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D and Cardiovascular Disease
Current Vascular Pharmacology Cognitive Functions under Anti-HER2 Targeted Therapy in Cancer Patients: A Scoping Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Polyarteritis Nodosa with Recurrent Skin Ulcers A Case Report
New Emirates Medical Journal Heme Oxygenase-1: A Potential Antihypertensive Target?
Current Hypertension Reviews Incidence of MicroR-4513C/T Gene Variability in Coronary Artery Disease - A case-Control Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Supraventricular Tachycardia in Fetus: How Can We Treat ?
Current Pharmaceutical Design Endothelin-1-Induced Signaling Pathways in Vascular Smooth Muscle Cells
Current Vascular Pharmacology Contextualizing Genetics for Regional Heart Failure Care
Current Cardiology Reviews Effect of an Obesogenic Diet During the Juvenile Period on Growth Pattern, Fatness and Metabolic, Cardiovascular and Reproductive Features of Swine with Obesity/Leptin Resistance
Endocrine, Metabolic & Immune Disorders - Drug Targets Endothelins and the Role of Endothelin Antagonists in the Management of Posttraumatic Vasospasm
Current Pharmaceutical Design Association of Rebleeding and Delayed Cerebral Ischemia with Long-term Mortality Among 1-year Survivors After Aneurysmal Subarachnoid Hemorrhage
Current Neurovascular Research Recent Advances in the Discovery and Development of Direct Coagulation Factor Xa Inhibitors
Current Pharmaceutical Design Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology Chemokines as Potential Therapeutic Targets in Atherosclerosis
Current Drug Targets Human Apolipoprotein C-III – A New Intrahepatic Protein Factor Promoting Assembly and Secretion of Very Low Density Lipoproteins
Cardiovascular & Hematological Disorders-Drug Targets Your Father and Grandfather’s Atrial Fibrillation: A Review of the Genetics of the Most Common Pathologic Cardiac Dysrhythmia
Current Genomics Medicinal Chemistry Approaches of Controlling Gastrointestinal Side Effects of Non-Steroidal Anti-Inflammatory Drugs. Endogenous Protective Mechanisms and Drug Design
Medicinal Chemistry Distinct MicroRNAs Identified in Rabbit Blood Arising from Induced Diabetes and a Surgically Simulated Diabetic Ischemia Complication
MicroRNA Development of Nitric Oxide Donors for the Treatment of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Adult Stem Cell Therapy for Cardiac Repair in Patients After Acute Myocardial Infarction Leading to Ischemic Heart Failure: An Overview of Evidence from the Recent Clinical Trials
Current Cardiology Reviews